Brooke

Join us tomorrow at 8:30 AM ET for a live call and webcast as we share our Q2 2023 results. Register here: social.jnj.com/3K1yWxd #earnings $JNJ

Agreement will expand access to key drug for resistant TB The agreement between Johnson & Johnson and Stop TB Partnership will make cheaper, generic versions of bedaquiline available in low- and middle-income nations ow.ly/eS5g50Pfulh Photo: USAID Asia / Flickr cc #AMR

For those curious how the global health community is responding to the news that bedaquiline generic access will be expanded.... (p.s. it just baffles me that @jnjnews has not released a statement beyond their catastrophic post yesterday. Do they ... need a marketing department?)

It's true, @JNJNews. We're starting to have feelings for you since you announced the deal to make generic bedaquiline available through the Stop TB Partnership. But we can't FULLY close this thrilling enemies-to-lovers romance until you - Commit to the deal with GDF in perpetuity. - Provide the list of countries that can access bedaquiline through this deal. - Publicly acknowledge this amounts to a functional abandonment of secondary patents on bedaquiline in countries with high TB burden. Say that in a tweet or press release, and IT'S ON.

Global Drug Facility Update on Access to Bedaquiline stoptb.org/news/global-dr…

Global Drug Facility Update on Access to Bedaquiline stoptb.org/news/global-dr…

Like many intentionally confusing corporate crisis response messages, this says a bunch of things that are true but don’t mean what you think, like for example: “On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023” This sounds like it says “everybody can have generic bedaquiline!!” But actually they *had to allow* the production of a generic because some countries had the power and systems in place to reject their attempt to extend their patent. The generic will not be available in countries where the patent extension wasn’t rejected, just like John said in his video. Unless that’s not the case @JNJNews!! If you’re telling us that you will allow the sale of generics anywhere in the developing world then we will happily send thank you baskets to your entire c-suite! Please let us know! Maybe we got it wrong and you only did the arduous work of extending the patent in a bunch of developing countries for funsies!